Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Crucell announces STAR(TM) Research License Agreement with Novo Nordisk A/S
- Leiden, The Netherlands, 16 January 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that it has signed a non-exclusive STARTM research license agreement for the production of monoclonal antibodies with Bagsvaerd, Denmark-based Novo Nordisk A/S. Novo Nordisk A/S intends to evaluate the STARTM technology using...
- Research articles 2007-01-16
Additional Resources
- From the Vault: Novo Nordisk's "Captain Novolin" Nightmare
- A reader wrote to me to complain that Pfizer was not a pioneer of drug-based video games, as I asserted its "Viva Cruiser" effort was for Viagra. She said: There was a game that Novo Nordisk put out about 15 years ago to promote their insulin called Captain Novolin....
- Blog posts 2008-09-06
- Novo Nordisk's Liraglutide Logos Leak Out Before Approval
- UPDATE: As BNET predicted, the new Novo Nordisk logos have been suddenly removed from the web. You can still see a Google cache of the page here, and a screen grab here. Novo Nordisk's new diabetes drug, liraglutide, isn't approved by the...
- Blog posts 2008-12-11
- Aradigm and Novo Nordisk Execute Further Restructuring of Partnership
- Aradigm Corporation (NASDAQ: ARDM) today announced the execution of an agreement further developing the strategic partnership with Novo Nordisk. The agreement is designed to strengthen Novo Nordisk's patent position within the area of inhaled insulin as related products progress towards commercialization and has resulted in a non-dilutive cash infusion to...
- Research articles 2006-07-05
- Novo Nordisk Expands R&D Presence in China with New Manufacturing Plant
- ChinaBio Today submits: Novo Nordisk NVO will invest almost $400 million to build a very large insulin manufacturing facility in Tianjin. The new facility will function as the company’s primary production site in China and serve the entire Asia Pacific region. The new 22,500 sq. meter plant, which will...
- External links 2008-11-11
- Novo Nordisk.(People)(Brief Article)
- * Novo Nordisk has appointed Alan C. Moses associate vice president of medical affairs in the United States. Moses comes to Novo Nordisk from the Joslin Diabetes Center and Joslin Clinic in Boston, where he was chief medical officer and senior vice president for the past five...
- Research articles 2004-06-01
- Novo Nordisk Executive Compensation: A Picture of Modesty (Except for the Car Expenses)
- Novo Nordisk's annual report is out and it contains some interesting stuff on senior management compensation. CEO Lars Rebien Sørensen received total compensation of DKK10.8 million (about $1.8 million). That was modest compared to his counterparts at American companies. (At Eli Lilly, CEO John Lechleiter got $13...
- Blog posts 2009-02-17
- Novo Nordisk to Implement Register™ From ArisGlobal® For its Regulatory Information Management System
- STAMFORD, Conn. -- ArisGlobal, a leading provider of safety, pharmacovigilance, regulatory, and medical information solutions, today announced that Novo Nordisk A/S, a world leader in diabetes care, has selected RegisterTM, as the backbone of its Regulatory Information Management System RIMS. A customized new version of RegisterTM, will be developed...
- Research articles 2005-10-26
- Genentech reviews appeals court decision regarding Novo Nordisk
- SAN FRANCISCO--BUSINESS WIRE--Feb. 27, 1996--On June 28, a district court in New York granted a preliminary injunction preventing Bio-Technology General and its affiliates BTG and Novo Nordisk A/S and its affiliates Novo from marketing their human growth hormone products in the United States. Subsequent to that decision, both companies...
- Research articles 1996-02-27
- Novo Nordisk to Implement Register(TM) From ArisGlobal(R) For its Regulatory Information Management System.
- STAMFORD, Conn., Oct 26, 2005 CCNMatthews via COMTEX -- ArisGlobal, a leading provider of safety, pharmacovigilance, regulatory, and medical information solutions, today announced that Novo Nordisk A/S, a world leader in diabetes care, has selected RegisterTM, as the backbone of its Regulatory Information Management System RIMS....
- Research articles 2005-10-26
- Xencor Completes $45 Million Financing with MedImmune Ventures, Novo Nordisk and HealthCare Ventures
- MONROVIA, Calif. -- Xencor, a company developing protein and antibody therapeutics, today announced that it raised $45 million in a private financing led by MedImmune Ventures, Inc., and including new investors Novo Nordisk and HealthCare Ventures as well as existing investor Zen Investments. The financing, which includes an initial $6...
- Research articles 2006-10-19
- Novo Nordisk's hemophilia drug linked to 67 deaths in US
- WASHINGTON AFP — NovoSeven, a hemophilia treatment by Danish firm Novo Nordisk, may have caused 67 deaths in the United States as well as cardiovascular complications, according to a study published in the Journal of the American Medical Association JAMA. In the study the Food and Drug Administration, which...
- Research articles 2006-01-18
- Dwayne Johnson, Novo Nordisk and the Entertainment Industry Foundation Educate Families about Healthy Living and Diabetes
- Johnson Asks Families to be Diabetes Aware in New Public Service Announcement PRINCETON, N.J. and LOS ANGELES, Aug. 12 /PRNewswire/ -- Dwayne Johnson joins with Novo Nordisk, a world-leader in diabetes care, and the Entertainment Industry Foundation EIF, a leading charitable organization of the entertainment industry,...
- Research articles 2009-08-12
- San Jose, Calif.-Based Biotech Company to Sell Stake to Danish Firm. (Originated from San Jose Mercury News, Calif.)
- SAN JOSE, Calif.--Aug. 24--Anergen Inc., a biotechnology company based in Redwood City, agreed Monday to sell a 17.5 percent stake to Novo Nordisk AS, a Danish pharmaceutical firm, for $8 million. SAN JOSE, Calif.--Aug. 24--Anergen Inc., a biotechnology company based in Redwood City, agreed Monday to...
- Research articles 1993-08-24
- New Yale Report to Show Devastating Impact of Diabetes Epidemic by 2025: Novo Nordisk to Launch National Changing Diabetes Program to Stem Tide of Diabetes Epidemic and Reduce Barriers to Prevention and Care
- WASHINGTON -- Results of a joint report by the Yale School of Public Health and Medicine and the Institute for Alternative Futures will be announced November 9. The report forecasts the dramatic consequences of the diabetes epidemic including projections in 2025 on the staggering number of deaths associated with diabetes...
- Research articles 2005-11-03
- Top 10 Weirdest Pharma Stories of the Month
- Sometimes I come across items that aren't important enough to count as news but are nonetheless too strange to ignore. Thus, I give you the top 10 weirdest drug stories for August: The connection between O.J. and Preparation H. Ever wonder why the orange juice in your...
- Blog posts 2008-08-29
- Drug Makers Gave Lobbyists an Xmas Gift -- Millions More to Lobby Obama Administration
- A New Year will bring a new president, a new FDA chief, many new drug regulations, and, possibly, health insurance reform. Mindful of the ton of major drug brands that will go off-patent in 2009, drug companies have not rested in their lobbying efforts over generics and patent issues. They...
- Blog posts 2008-12-31
- "Novartis Land" the Latest Entry in Weird Drug-Based Video Game Trend
- Teva might want to ask Novartis where the latter got its idea for "Novartis Land," the HR video game that Novartis employees are asked to play in order to teach them about ethics. Novartis Land bears a strong resemblance to Teva's game, "Biologicsland." BNET readers will remember...
- Blog posts 2009-03-23
- Eli Lilly and Alkermes Form Pact for Inhaled Insulin Products.(Brief Article)
- ELI LILLY AND COMPANY has shored up its diabetes franchise by signing a deal to develop inhaled insulin and other diabetes care products with Alkermes Inc. Lilly joins Novo Nordisk, Pfizer and Aventis as major drug companies developing inhaled insu ELI LILLY AND COMPANY...
- Research articles 2001-04-09
- Rating and Ranking "Stealth Pharmas"
- A "stealth pharma," according to the folks at Pharmaceutical Executive, is any drug company that's not a Big Pharma. In other words, it's grab-bag of outfits that includes everything from specialty pharmas hawking retread drugs to biotechs to generics makers. Which, of course, makes them difficult to...
- Blog posts 2008-06-26
- << Previous
- page 1 of 1
- Next >>
